Autopsy report · NCT04352205

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

“Slow accrual”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 8 months before it stopped.
• 17 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Emory University

Sponsor type

University, hospital or other

Conditions

Plasma Cell Myeloma; Renal Failure

Interventions

Bortezomib; Daratumumab; Dexamethasone; Lenalidomide; Thalidomide

Participants

17

Sites

1

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.